If it was a good day for Bothell’s MedManage, which raised $10.75 million, it was a GREAT day for Corus Pharma of Seattle, which announced a $25-million investment from Gilead Sciences Inc. of California.
Details of the detail can be found here, http://www.businessweek.com/ap/financialnews/D8GUML907.htm?campaign_id=apn_home_down&chan=db, or here, http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20060412&ID=5640879.
It was just two months ago that Corus, which employs about 100 people, scrapped plans for its IPO. And it’s still involved in a legal scrap with Chiron. So Gilead’s investment doesn’t get Corus out of the woods, but it sure helps.